CAMSING HEALTHCARE LIMITED

(Company Registration Number: 197903888Z) (Incorporated in the Republic of Singapore)

FULFILMENT OF TRADE RESUMPTION CONDITIONS

Capitalised terms in this announcement shall have the same meanings as ascribed to them in the Previous Announcements (as defined below) unless otherwise defined.

1. INTRODUCTION

The Board of Directors (the "Board") of Camsing Healthcare Limited (the "Company" and together with its subsidiaries, the "Group") refers to the following announcements:

- (a) the announcement dated 14 June 2023 in relation to the entry into the New Investment Agreement and the termination of the QRH Investment Documents;
- (b) the announcement dated 15 June 2023 in relation to the submission of the Resumption Proposal to SGX RegCo;
- (c) the announcement dated 6 February 2024 with an update on the New Investment;
- (d) the announcement dated 3 May 2024 in relation to the receipt of AIP in respect of the listing and quotation of the Subscription Shares and the Conversion Shares (the "L&Q AIP");
- (e) the announcements dated 9 May 2024, 24 May 2024 and 19 June 2024, in connection with the Company's extraordinary general meeting to approve resolutions in connection with the New Investment;
- (f) the announcement dated 10 May 2024 in relation to the receipt of AIP in respect of the Resumption Proposal (the "Resumption AIP"); and
- (g) the announcement dated 3 July 2024 in relation to the completion of the New Investment (the "New Investment Completion Announcement"),

(collectively, the "Previous Announcements").

2. FUFILMENT OF THE RESUMPTION CONDITIONS

2.1 The Board wishes to announce that the Company has fulfilled the relevant conditions in connection with the Resumption AIP (the "**Resumption Conditions**"), details of which are as follows:

Fulfilment of the conditions in connection with the L&Q AIP (the "L&Q Conditions")

- (a) The Company has fulfilled the relevant L&Q Conditions and confirms that:
 - (i) the Company is in compliance with SGX-ST's continuing listing requirements;
 - (ii) the Company has provided a written undertaking that it will comply with Listing Rules 740(30) and 1207(20) in relation to the use of the proceeds from the Proposed Placement and where proceeds are to be used for working capital purposes, and the Company will disclose a breakdown with specific details on the use of proceeds for working capital in the Company's announcements on use of proceeds and in the annual report; and

- (iii) the Company has provided a written confirmation that the Proposed Placement and Bonds do not contravene any laws and regulations governing the Company and the constitution of the Company.
- (b) As the Proposed Placement and Proposed Issuance have been completed, the proceeds from the Proposed Placement and Proposed Issuance have been released from escrow to the Company.
- (c) The Company will source and appoint one (1) additional independent director within three (3) months of the listing and quotation of the Subscription Shares and the Conversion Shares, in which such independent director shall be sourced via a third-party independent selection process and shall be subject to SGX-ST's approval.

Completion of the placement of all the Subscription Shares and the issuance of all the Bonds to the investors

(d) As set out in the New Investment Completion Announcement, the placement of all the Subscription Shares and the issuance of all the Bonds to the investors have been completed.

3. REQUEST FOR RESUMPTION OF TRADING

Following the fulfilment of the Resumption Conditions, the Company will be seeking separate concurrent confirmation from the SGX RegCo on the date for resumption of trading and will update the Shareholders accordingly.

Shareholders are advised to exercise caution when dealing in the shares of the Company. Persons who are in doubt as to the action they should take should consult their stockbrokers, bank managers, solicitors, accountants or other professional advisors.

BY ORDER OF THE BOARD

Yeo Choon Tat Executive Director 3 July 2024